Actively Recruiting
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
Led by Augusta University · Updated on 2025-01-28
24
Participants Needed
1
Research Sites
350 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.
CONDITIONS
Official Title
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and premenopausal women
- All races
- Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)
You will not qualify if you...
- Clinical diagnosis of hepatic, cardiovascular, or renal disease
- Uncontrolled diabetes (HbA1C >12%)
- Diabetic complications (i.e. neuropathy)
- Uncontrolled hypertension (>140/90 mm Hg on therapy)
- Pregnancy
- Use of vasoactive medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology
Augusta, Georgia, United States, 30912
Actively Recruiting
Research Team
R
Ryan A Harris, PhD, CEP
CONTACT
J
Jacob Looney, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here